HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES - February 28, 2024

28 Feb 2024
PLYMOUTH MEETING, Pa., Feb. 28, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences: Leerink Partners Global Biopharma Conference 2024 Location: Miami Fireside Chat: Monday, March 11, 2024, at 12:40 p.m. ET Barclays 26th Annual Global Healthcare Conference Location: Miami Fireside Chat: Tuesday, March 12, 2024, at 3:35 p.m. ET A webcast of the fireside chats will be available on the investor page of Harmony's website at . About Harmony Biosciences At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that where empathy and innovation meet, a better life can begin for people living with neurological diseases. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, our team of experts from a wide variety of disciplines and experiences is driven by our shared conviction that innovative science translates into therapeutic possibilities for our patients, who are at the heart of everything we do. For more information, please visit . Harmony Biosciences Investor Contact: Luis Sanay, CFA 445-235-8386 lsanay@harmonybiosciences.com Harmony Biosciences Media Contact: Cate McCanless 202-641-6086 cmccanless@harmonybiosciences.com Company Codes: NASDAQ-NMS:HRMY
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.